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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Does
lisdexamfetamine dimesylate (Vyvanse) reduce the weekly incidence of binge eating in adults
with binge eating disorder?”
Study Design: A systematic review of three double-blind, randomized, placebo-controlled trials
published between 2015 and 2017.
Data Sources: All articles were obtained from PubMed and were published in peer-reviewed
journals, in the English language. They were selected based on their applicability to the clinical
question, credibility, and if the researched outcomes were patient oriented.
Outcomes Measured: The number of binge eating days per week was the outcome measured,
with the data compiled from self-reported diaries and clinical interviews. The mean value of
binge eating days per week ± standard deviation for both the placebo and intervention group was
calculated at two time points, before the trial started and at the end of the trial. The mean change
from baseline was then calculated.
Results: The study conducted by McElroy et al. demonstrated a statistically significant reduction
(p-value < 0.001) in the number of binge eating days per week with lisdexamfetamine dimesylate
70mg, with a mean change from baseline of 4.1. In the study conducted by Hudson et al.,
lisdexamfetamine dimesylate 70mg led to a statistically significant reduction (p-value < 0.001) in
the number of binge eating days per week, indicated by a mean change from baseline of 4.72.
The study conducted by Guerdjikova et al. revealed a statistically significant reduction (p-value
= 0.03) in the number of binge eating days per week with lisdexamfetamine dimesylate 70mg,
with a mean change from baseline of 3.4.
Conclusion: The results of these three studies demonstrated that the use of lisdexamfetamine
dimesylate 70mg led to a statistically significant reduction in the number of binge eating days
per week in adults diagnosed with binge eating disorder.
Key Words: binge eating disorder, lisdexamfetamine
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INTRODUCTION
Binge eating disorder (BED) is defined as recurrent episodes of uncontrolled eating, in
which an individual consumes large amounts of food within short periods of time. BED is the
most common eating disorder in the United States, with a lifetime prevalence of 3.6% for women
and 2.1% for men.1 While the etiology of BED is unknown, it is believed to be multifactorial.
Factors that are thought to put an individual at a higher risk for developing BED include
childhood obesity and negative family dynamics and upbringings. 1 To establish a diagnosis of
BED, an individual must meet the diagnostic criteria outlined by the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5). An individual must have episodes of binge
eating at least once a week for three months, plus at least three of the following associated
behaviors: eating faster than normal, eating until uncomfortably full, eating despite not feeling
hungry, eating alone to avoid embarrassment, feeling guilty after eating. 1 BED is clinically
distinguishable from bulimia nervosa, as individuals with BED do not compensate for their
excessive caloric intake with measures including laxative use or self-induced vomiting. 1
Furthermore, individuals with BED are often average weight or overweight and do not have
goals revolving around obtaining extreme thinness, which are differentiating characteristics that
are present in an individual with anorexia nervosa. 1
With increasing prevalence and recognition of feeding and eating disorders in the United
States, there is a need for applicable research involving these conditions. In 2018-2019, the total
financial costs associated with eating disorders was an estimated $64.7 billion, with a total of
$19.4 billion (30%) spent on BED specifically.2 Additionally, from 2018-2019 there were
approximately 8,000 emergency department visits, resulting in 5,600 inpatient admissions
associated with eating disorders.2 It is estimated that individuals diagnosed with eating disorders
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saw a mental health professional 35.8 more times and a primary care provider 3.0 more times
compared to the general population.2 The role of physician assistants (PAs) in the care of
individuals with psychiatric disorders is important to include in this discussion as 62% of PAs, in
2015, helped care for individuals with mental health conditions, with the highest percentage of
these healthcare professionals working in psychiatry, followed by internal medicine, emergency
medicine, and family medicine.3 As of 2015, 1.6% of credentialed PAs worked in psychiatry. 3
The existing approach for the treatment of binge eating disorder can be broken down into
two distinct categories, cognitive behavioral therapy (CBT) and pharmacologic therapy. While
CBT is currently the most researched and supported treatment method for BED, not all
individuals have access to this therapy; additionally, not all patients will respond to this
treatment method.4 Examples of pharmacologic therapy that have been utilized in the treatment
of BED, but are not FDA approved, include antidepressant medications and anticonvulsant
medications.1 Lisdexamfetamine dimesylate is an additional medication that has promising,
ongoing research for its use in the treatment of binge eating disorder. Lisdexamfetamine
dimesylate is a psychostimulant that inhibits the presynaptic neuronal reuptake of dopamine and
norepinephrine, resulting in increased levels of these neurotransmitters in the brain. 5 Though
most commonly recognized for its use in the treatment of attention deficit hyperactivity disorder,
lisdexamfetamine dimesylate was approved by the FDA in 2015 for the treatment of BED. 1
While the exact mechanism of action in reducing binge eating episodes in those with BED is
unknown, it is thought to improve impulse control.4 This paper analyzes three randomized
controlled trials that study the use of lisdexamfetamine dimesylate and its ability to reduce the
number of binge eating days per week in those diagnosed with binge eating disorder.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does
lisdexamfetamine dimesylate (Vyvanse) reduce the weekly incidence of binge eating in adults
with binge eating disorder?”
METHODS
The studies referenced in this EBM review were found on PubMed using the key words
“lisdexamfetamine” and “binge eating disorder.” Inclusion criteria comprised studies that were
published in the past 10 years, were randomized controlled trials, were written in the English
language, and included humans as the subjects of the study. Exclusion criteria eliminated studies
that were published before 2011. It was required that the studies employed randomization and
were published in peer-reviewed journals. Statistical analyses that were utilized in these selected
randomized controlled trials included p-values and standard deviations. All studies were chosen
based on credibility, applicability to the clinical question, and incorporation of patient-oriented
outcomes.
This EBM review includes studies that have comparable populations, interventions,
comparisons, and outcomes measured. The target population for this EBM review includes adults
between the ages of 18 and 55 who were clinically diagnosed with binge eating disorder. The
intervention being investigated is lisdexamfetamine dimesylate 70mg per day compared to a
physically identical placebo. The outcome being measured in this review is the number of binge
eating days per week. The demographics and characteristics of these studies can be found in
Table 1.
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Table 1 - Demographics & Characteristics of Included Studies
Study

Type

McElroy Double
(2015) 4 Blind
RCT

Hudson
(2017) 6

Double
Blind
RCT

Guerdjik Double
ova
Blind
(2016) 7 RCT

#
Pts
260

Age
(yrs)
1855

Inclusion
Criteria
Adults (1855 yo); met
the DSMIV-TR
diagnostic
criteria for
BED; BMI
25 to 45

275

1855

50

1855

Adults (1855 yo); met
the DSMIV-TR
diagnostic
criteria for
BED;
protocoldefined
moderate to
severe BED
(>3 BE
days/ week
x 2 weeks
prior to
study); BMI
18 to 45
Adults (1855 yo); met
the DSMIV-TR
diagnostic
criteria for
BED; >3
BE
days/week x
2 weeks
prior to the
study

Exclusion Criteria

W/
D
58

Current bulimia,
anorexia, ADHD,
other psychiatric
disorder;
psychological or
weight loss
interventions (past 3
months);
psychostimulant use
(past 6 months); total
MADRS score of 18
or higher; personal or
family hx of CVD; hx
of substance abuse
Current bulimia,
123
anorexia, suicidal
ideation, other
psychiatric disorder;
past suicide attempt;
psychotherapy or
weight loss support for
BED (past 3 months);
psychostimulant use
(past 6 months); hx of
CVD; significant ECG
abnormalities; hx of
substance abuse

Current bulimia,
anorexia, suicidal
ideation; suicide
attempt (past year);
psychological or
weight loss
intervention for BED
(past 3 months); hx of
substance use
disorder; significant
laboratory or ECG
abnormalities

23

Intervention
s
lisdexamfet
amine
dimesylate
30mg,
50mg, or
70mg
versus
placebo

lisdexamfet
amine
dimesylate
70mg
versus
placebo

lisdexamfet
amine
dimesylate
70mg
versus
placebo
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OUTCOME MEASURED
All three studies included in this EBM review utilized self-reported diaries and clinical
interviews to obtain and verify the number of binge eating days per week for each individual
participating in the study. The number of binge eating days per week for each subject was
established before the study started and at the end of the study. The data was complied,
calculated, and then reported as a mean value ± standard deviation for both the placebo and
intervention groups. Additionally, a p-value was reported for the intervention group and the
mean change from baseline was then calculated.
RESULTS
McElroy et al. conducted a randomized, double blind, placebo-controlled trial, with
results of the study published in 2015.4 A total of 260 participants were selected between the
ages of 18 and 55 and met the diagnostic criteria for BED. Using a web-based system, subjects
were randomized at a 1:1:1:1 ratio to receive the intervention of lisdexamfetamine dimesylate at
a maintenance dose of 30mg, 50mg, or 70mg versus an identical placebo. Blinding was
maintained throughout the trial by having the placebo and lisdexamfetamine dimesylate
indistinguishable by size, shape, weight, and color. This study consisted of a three week dose
titration phase followed by an eight week maintenance phase, for a total of an 11 week trial. The
subjects that were receiving the active treatment were all started at 30mg and were titrated
weekly, by 20mg, up to their assigned dose. In order to maintain consistency between all three
studies discussed in this EBM review, the focus of this article will be the intervention group with
a maintenance dose of 70mg. The intervention group, with a maintenance dose of 70mg, lost 13
participants total. Three subjects were lost due to adverse events, one being due to
methamphetamine overdose (not related to the study drug), and the remaining 10 participants
were lost due to protocol violations, lack of follow up, and withdrawal by the subject. 4 No
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participants in the study were lost due to lack of efficacy. Though not leading to withdrawal from
the study, both the placebo and intervention group experienced adverse events, the most
commonly reported being dry mouth, decreased appetite, and insomnia. 4
The primary outcome analyzed in this study was the number of binge eating days per
week, measured as the mean number of binge eating days per week, and standard deviation,
before treatment and at the end of the trial at week 11. The outcome was analyzed through
clinical interviews and reviews of self-reported diaries. The results of this study are summarized
in Table 2 below. The placebo group showed a decrease in binge eating days per week with a
baseline of 4.3±1.38 to 1.1±1.45 at week 11, with a mean change from baseline calculated as
3.2.4 The 70mg intervention group exhibited a statistically significant decrease in binge eating
days per week with a baseline of 4.6±1.25 to 0.5±1.25 at week 11, with a mean change from
baseline calculated as 4.1, and a p-value of < 0.001.4
Table 2. Mean Change in Binge Eating Days/Week from Baseline to Week 11
Group

Before
Treatment
(Mean
± Standard
Deviation)
Placebo
4.3±1.38
lisdexamfetamine 4.6±1.25
dimesylate 70mg

After
Treatment
(Mean
± Standard
Deviation)
1.1±1.45
0.5±1.25

Mean Change
from Baseline
(calculated)

P value

3.2
4.1

Not reported
< 0.001

Hudson et al. conducted a two-phase trial consisting of a 12 week open label phase,
followed by a 26 week randomized, double blind, placebo-controlled trial. 6 To maintain
consistency between all three studies in this EBM review, the focus of this article will be on the
findings reported from the randomized controlled trial. All 275 subjects that were selected to be
in this study were between the ages of 18 and 55 and met the diagnostic criteria for BED.
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Subjects were randomized using a web-based system, at a 1:1 ratio, to receive a placebo versus
70mg of lisdexamfetamine dimesylate. Blinding was maintained throughout the trial by having
the placebo and lisdexamfetamine dimesylate identical in appearance. The intervention group
lost 35 total participants: two to protocol violations, nine to withdrawal by the participant, six to
loss of follow up, five to meeting relapse criteria, and seven to other reasons. Six subjects in the
intervention group were lost due to adverse events, two of which were reported due to breast
cancer and nerve root compression.6 The top adverse events that did not lead to withdrawal from
the study, that were reported by both the placebo and intervention group, included headache,
nasopharyngitis, and fatigue.6
The outcome, the number of binge eating days per week, was analyzed through clinical
interviews and reviews of self-reported diaries. The results of this study are summarized in Table
3 below. The placebo group showed a decrease in binge eating days per week with a baseline of
4.71±1.23 to 0.26±0.465 at week 38.6 The intervention group demonstrated a decrease in binge
eating days per week with a baseline of 4.80±1.19 to 0.08±0.239 at week 38, with a mean
change from baseline of 4.72.6 The p-value for the intervention group was reported as < 0.001,
which is a statistically significant finding.6
Table 3. Mean Change in Binge Eating Days/Week from Baseline to Week 38
Group

Before
Treatment
(Mean
± Standard
Deviation)
Placebo
4.71±1.23
lisdexamfetamine 4.80±1.19
dimesylate 70mg

After
Treatment
(Mean
± Standard
Deviation)
0.26±0.465
0.08±0.239

Mean Change
from Baseline
(calculated)

P value

4.45
4.72

Not reported
< 0.001
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Published in 2016, Guerdjikova et al. conducted a 12 week, randomized, double blind,
placebo-controlled trial.7 All patients selected were between the ages of 18 and 55 and met the
diagnostic criteria for BED. A total of 50 participants were randomized using a web-based
system, at a 1:1 ratio, to receive lisdexamfetamine dimesylate or the identical placebo. The
dosage of lisdexamfetamine dimesylate started at 30mg and was titrated up to 50mg during week
two. During week three, lisdexamfetamine dimesylate was titrated up to the maintenance dose
which was defined as 70mg. With a total of 23 participants not completing the trial, 19 subjects
were lost due to scheduling difficulties and loss of follow up. 7 Furthermore, two subjects in both
the treatment and placebo group experienced adverse events which led them to discontinue the
trial. In the intervention group, one subject experienced severe chest pain and the other
experienced insomnia.7 In the placebo group, one subject was diagnosed with pneumonia and the
other experienced exacerbation of past obsessions. 7 Other adverse events that were reported but
did not result in withdrawal from the study included dry mouth, jitteriness, and headache. 7 These
adverse events were reported by subjects in both groups; however, subjects in the intervention
group reported them occurring more frequently.
The primary outcome measured in this trial was the number of binge eating days per
week, reported as the mean number, including standard deviation, before treatment and at the
end of the trial. Data directly related to the primary outcome was collected and analyzed through
clinical interviews and self-reported diaries. The results of this study are summarized in Table 4
below. The placebo group demonstrated a decrease in binge eating days per week with a baseline
of 4.1±1.1 to 1.8±1.8 at week 12, resulting in a mean change from baseline of 2.3. 7 The
intervention group revealed a decrease in binge eating days per week with a baseline of 4.3±1.3
to 0.9±1.3 at week 12, resulting in a mean change from baseline of 3.4. 7 The data presented
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represents a statistically significant change for intervention group, with a reported p-value of
0.03.7
Table 4. Mean Change in Binge Eating Days/Week from Baseline to Week 12
Group

Before
Treatment
(Mean
± Standard
Deviation)
Placebo
4.1±1.1
lisdexamfetamine 4.3±1.3
dimesylate 70mg

After
Treatment
(Mean
± Standard
Deviation)
1.8±1.8
0.9±1.3

Mean Change
from Baseline
(calculated)

P value

2.3
3.4

Not reported
0.03

DISCUSSION
With binge eating disorder reported as the most common eating disorder in the United
States, there is a need for safe and effective treatments. This EBM review assessed
lisdexamfetamine dimesylate as a reliable treatment method for adults diagnosed with binge
eating disorder. The findings reported from all three articles demonstrated a statistically
significant reduction in the number of binge eating days per week in subjects receiving the
intervention of lisdexamfetamine dimesylate 70mg. McElroy et al. reported a p-value of < 0.001
with a mean change from baseline of 4.1, Hudson et al. reported a p-value of < 0.001 with a
mean change from baseline of 4.72, and Guerdjikova et al. reported a p-value of 0.03 with a
mean change from baseline of 3.4 for the intervention group. These results aid in validating the
efficacy of lisdexamfetamine dimesylate and support its role in treating binge eating disorder.
With a decrease in the number of binge eating days per week in individuals taking this
medication, there is a subsequent improvement in the quality of life of these individuals
diagnosed with binge eating disorder.
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While all three studies discussed in this EBM review were double blind, randomized,
placebo-controlled trials, which increases the validity of the studies, there are some limitations
that need to be addressed. The studies conducted by McElroy et al. and Guerdjikova et al. were
short in duration, making it difficult to generalize the long-term efficacy and safety of the
intervention. The study completed by Guerdjikova et al. also had a small sample size, making it
difficult to generalize the results. Additionally, all three studies in this EBM review excluded
subjects that had comorbid psychiatric disorders. Research shows that those diagnosed with
binge eating disorder are likely to have comorbid psychiatric disorders, so excluding these
individuals from the trials makes it difficult to draw conclusions regarding the efficacy and
safety of the intervention in these populations.1 Lastly, all three studies had the greatest
percentage of subjects being Caucasian females, resulting in the inability to rationalize the
findings of the intervention to other demographics including the male population and those of
other races.
While the efficacy and benefit of lisdexamfetamine dimesylate in the treatment of binge
eating disorder has been thoroughly discussed in this EBM review, this medication comes with
barriers to its use. Per the medication website, the most common side effects experienced from
the use of this medication include dry mouth, decreased appetite, insomnia, feeling jittery,
headache, and increased heart rate.8 Lisdexamfetamine dimesylate also presents with some abuse
and addiction potential, as it is categorized as a schedule II controlled substance. 8
Lisdexamfetamine dimesylate is not a medication that every individual with binge eating
disorder can take; therefore, its use should be thoroughly discussed with a healthcare
professional before initiation.
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CONCLUSION
This systemic review revealed lisdexamfetamine dimesylate to be effective in decreasing
the number of binge eating days per week in individuals diagnosed with binge eating disorder;
therefore, increasing quality of life in these individuals. McElroy et al., Hudson et al., and
Guerdjikova et al. all found lisdexamfetamine dimesylate 70mg to produce a statistically
significant mean decrease in the number of binge eating days per week from the beginning of the
study to the end. In order to further determine a place in therapy for lisdexamfetamine dimesylate
in the treatment of BED, additional trials should be performed with larger sample sizes and for
longer durations of time to assess the long-term effectiveness and safety of this medication.
Other future studies of benefit include those that incorporate subjects of all demographics and
those with comorbid psychiatric conditions. It would also be of interest to explore the
combination of both lisdexamfetamine dimesylate and CBT to further optimize treatment
efficacy. A final consideration is to create future studies that compare the use of
lisdexamfetamine dimesylate to the other pharmacologic treatments that have the potential to be
effective but have not been studied yet in comparison. With the increasing incidence and
recognition of binge eating disorder, these future studies are warranted to provide the best
treatment regimen for those with binge eating disorder, resulting in the most beneficial patient
oriented outcomes.
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